Yıl: 2021 Cilt: 32 Sayı: 8 Sayfa Aralığı: 685 - 693 Metin Dili: İngilizce DOI: 10.5152/tjg.2021.20677 İndeks Tarihi: 18-05-2022

Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study

Öz:
Background: A small proportion of all hepatocellular carcinomas (HCCs) arise in a non-cirrhotic liver (NCL). However, our knowledge about the HCCs developing in a NCL is scarce. This study was undertaken to investigate the characteristics and survival course of this patient group. Methods: We retrospectively analyzed the database of patients with HCC at a tertiary center during a 10-year period (2009-2019). All demographic, clinical, laboratory, and tumoral features with survival outcomes were compared between the HCC-CL and HCC-NCL groups. Results: Out of 384 HCC cases, 11.2% (n = 43) had no cirrhosis. The dominant etiology in the HCC-NCL group was hepatitis B virus (n = 26, 60.5%), followed by non-alcoholic fatty liver disease (n = 10, 23.2%), and hepatitis C virus (n = 7, 16.3%). The maximum tumor diameter was approximately 2 times larger in the HCC-NCL group (HCC-NCL: 90 mm vs. HCC-CL: 46.5 mm, P < .001). The proportion of patients with vascular (HCC-NCL: 27.9% vs. HCC-CL: 8.6%, P < .001) and extrahepatic invasion (HCC-NCL: 14% vs. HCC-CL: 3%, P = .001) were prominently higher in the HCC-NCL group. Patients with HCC-NCL were less often detected in early-curable stages (BCLC 0-A) than those in the HCC-CL group (HCC-NCL: 16.3% vs. HCC-CL: 34.9%, P = .004). The overall survival was not different between the 2 groups (HCC-NCL: 19.4 ± 9.8 months vs. HCC-CL: 17.5 ± 2.3 months, P = .581). Conclusion: HCC in NCL is diagnosed at more advanced tumoral stages with larger tumor size and more often with vascular and extrahepatic spread. Despite the preserved liver functions, the overall survival is not prolonged in HCCs without cirrhosis, due to the late recognition.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953. [CrossRef]
  • 2. Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int. 2019;39(6):1098-1108. [CrossRef ] 3. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci. 2015;60(10):3142-3148. [CrossRef]
  • 4. Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol. 2010;16(32):4061-4065. [CrossRef]
  • 5. Albeldawi M, Soliman M, Lopez R, Zein NN. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients. Dig Dis Sci. 2012;57(12):3265-3270. [CrossRef]
  • 6. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12(8):509-522. [CrossRef]
  • 7. Chu YJ, Yang HI, Wu HC, et al. Aflatoxin b1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer. 2017;141(4):711-720. [CrossRef]
  • 8. Hiatt T, Trotter JF, Kam I. Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci. 2007;334(3):228-230. [CrossRef]
  • 9. Topic A, Ljujic M, Radojkovic D. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC):e7042. [CrossRef]
  • 10. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer. 2017;48(3):238-240. [CrossRef]
  • 11. Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol. 2019;31(7):743-748. [CrossRef]
  • 12. Akkiz H, Carr BI, Yalçın K KK, et al. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology. 2018;94(2):116-124. [CrossRef]
  • 13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. [CrossRef]
  • 14. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated With nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124-31.e1. [CrossRef]
  • 15. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329- 338. [CrossRef]
  • 16. Amin MB, Edge S, Greene F et al. AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.
  • 17. van Meer S, van Erpecum KJ, Sprengers D, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2016;28(3):352-359. [CrossRef]
  • 18. Weinmann A, Koch S, Niederle IM, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol. 2014;48(3):279-289. [CrossRef]
  • 19. Schütte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the noncirrhotic liver. BMC Gastroenterol. 2014;14:117. [CrossRef]
  • 20. Gawrieh S, Dakhoul L, Miller E, et al. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther. 2019;50(7):809-821. [CrossRef]
  • 21. Xu L, Huang L, Li BK, et al. Clinicopathologic features and longterm outcomes of Chinese patients with hepatocellular carcinoma in non-cirrhotic liver. Dig Surg. 2008;25(5):376-382. [CrossRef]
  • 22. Nojiri K, Nagano Y, Tanaka K, et al. The influence of viral hepatitis status on long-term HCC outcome in patients with non-cirrhotic livers. Anticancer Res. 2011;31(3):1055-1059.
  • 23. Giannini EG, Marenco S, Bruzzone L, et al. Hepatocellular carcinoma in patients without cirrhosis in Italy. Dig Liver Dis. 2013;45(2):164-169. [CrossRef]
  • 24. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis. 2010;42(5):341-347. [CrossRef]
  • 25. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188-2195. [CrossRef]
  • 26. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723-1730. [CrossRef]
  • 27. Privitera G, Spadaro L, Marchisello S, Fede G, Purrello F. Abnormalities of lipoprotein levels in liver cirrhosis: clinical relevance. Dig Dis Sci. 2018;63(1):16-26. [CrossRef]
  • 28. Mei Y, You Y, Xia J, Gong JP, Wang YB. Identifying differentially expressed microRNAs Between cirrhotic and non-cirrhotic hepatocellular carcinoma and exploring their functions using bioinformatic analysis. Cell Physiol Biochem. 2018;48(4):1443-1456. [CrossRef]
  • 29. Witjes CD, Polak WG, Verhoef C, et al. Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers. Dig Surg. 2012;29(6):522- 528. [CrossRef]
  • 30. Wörns MA, Bosslet T, Victor A, et al. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol. 2012;47(6):718-728. [CrossRef]
  • 31. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. [CrossRef]
  • 32. Demirtas CO, Gunduz F, Tuney D, et al. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. Eur J Gastroenterol Hepatol. 2020;32(4):517-523. [CrossRef]
  • 33. Demirtas CO, Gunduz F, Kani HT, et al. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. Eur J Gastroenterol Hepatol. 2020;32(7):882-888. [CrossRef]
APA Demirtas C, Tolu T, Keklikkiran C, ozdogan o, Dilber F (2021). Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. , 685 - 693. 10.5152/tjg.2021.20677
Chicago Demirtas Coskun,Tolu Tugba,Keklikkiran Caglayan,ozdogan osman,Dilber Feyza Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. (2021): 685 - 693. 10.5152/tjg.2021.20677
MLA Demirtas Coskun,Tolu Tugba,Keklikkiran Caglayan,ozdogan osman,Dilber Feyza Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. , 2021, ss.685 - 693. 10.5152/tjg.2021.20677
AMA Demirtas C,Tolu T,Keklikkiran C,ozdogan o,Dilber F Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. . 2021; 685 - 693. 10.5152/tjg.2021.20677
Vancouver Demirtas C,Tolu T,Keklikkiran C,ozdogan o,Dilber F Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. . 2021; 685 - 693. 10.5152/tjg.2021.20677
IEEE Demirtas C,Tolu T,Keklikkiran C,ozdogan o,Dilber F "Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study." , ss.685 - 693, 2021. 10.5152/tjg.2021.20677
ISNAD Demirtas, Coskun vd. "Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study". (2021), 685-693. https://doi.org/10.5152/tjg.2021.20677
APA Demirtas C, Tolu T, Keklikkiran C, ozdogan o, Dilber F (2021). Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. Turkish Journal of Gastroenterology, 32(8), 685 - 693. 10.5152/tjg.2021.20677
Chicago Demirtas Coskun,Tolu Tugba,Keklikkiran Caglayan,ozdogan osman,Dilber Feyza Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. Turkish Journal of Gastroenterology 32, no.8 (2021): 685 - 693. 10.5152/tjg.2021.20677
MLA Demirtas Coskun,Tolu Tugba,Keklikkiran Caglayan,ozdogan osman,Dilber Feyza Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. Turkish Journal of Gastroenterology, vol.32, no.8, 2021, ss.685 - 693. 10.5152/tjg.2021.20677
AMA Demirtas C,Tolu T,Keklikkiran C,ozdogan o,Dilber F Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. Turkish Journal of Gastroenterology. 2021; 32(8): 685 - 693. 10.5152/tjg.2021.20677
Vancouver Demirtas C,Tolu T,Keklikkiran C,ozdogan o,Dilber F Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study. Turkish Journal of Gastroenterology. 2021; 32(8): 685 - 693. 10.5152/tjg.2021.20677
IEEE Demirtas C,Tolu T,Keklikkiran C,ozdogan o,Dilber F "Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study." Turkish Journal of Gastroenterology, 32, ss.685 - 693, 2021. 10.5152/tjg.2021.20677
ISNAD Demirtas, Coskun vd. "Hepatocellular Carcinoma in Non-cirrhotic Liver Arises with a More Advanced Tumoral Appearance: A Single-Center Cohort Study". Turkish Journal of Gastroenterology 32/8 (2021), 685-693. https://doi.org/10.5152/tjg.2021.20677